Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Deactivation of human immunodeficiency virus type 1 in medium by copper oxide-containing filters.

Borkow G, Lara HH, Covington CY, Nyamathi A, Gabbay J.

Antimicrob Agents Chemother. 2008 Feb;52(2):518-25. Epub 2007 Dec 10.

2.

Prevention of human immunodeficiency virus breastmilk transmission with copper oxide: proof-of-concept study.

Borkow G, Covington CY, Gautam B, Anzala O, Oyugi J, Juma M, Abdullah MS.

Breastfeed Med. 2011 Aug;6(4):165-70. doi: 10.1089/bfm.2010.0090.

PMID:
21770731
3.
4.

Neutrophils from human immunodeficiency virus (HIV)-seronegative donors induce HIV replication from HIV-infected patients' mononuclear cells and cell lines: an in vitro model of HIV transmission facilitated by Chlamydia trachomatis.

Ho JL, He S, Hu A, Geng J, Basile FG, Almeida MG, Saito AY, Laurence J, Johnson WD Jr.

J Exp Med. 1995 Apr 1;181(4):1493-505. Erratum in: J Exp Med 1999 Nov 1;190(9):following 1362.

5.

Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate.

Krebs FC, Miller SR, Malamud D, Howett MK, Wigdahl B.

Antiviral Res. 1999 Oct;43(3):157-73.

PMID:
10551374
6.

Neutralizing viruses in suspensions by copper oxide-based filters.

Borkow G, Sidwell RW, Smee DF, Barnard DL, Morrey JD, Lara-Villegas HH, Shemer-Avni Y, Gabbay J.

Antimicrob Agents Chemother. 2007 Jul;51(7):2605-7. Epub 2007 Apr 30.

7.

Human peripheral blood mononuclear cell substrate for propagating wild type HIV-1.

Vyas GN.

Dev Biol (Basel). 2001;106:345-56; discussion 356-7.

PMID:
11761248
9.
10.
11.
12.

N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery.

Pollock S, Dwek RA, Burton DR, Zitzmann N.

AIDS. 2008 Oct 1;22(15):1961-9. doi: 10.1097/QAD.0b013e32830efd96.

PMID:
18753929
13.

A novel anti-influenza copper oxide containing respiratory face mask.

Borkow G, Zhou SS, Page T, Gabbay J.

PLoS One. 2010 Jun 25;5(6):e11295. doi: 10.1371/journal.pone.0011295.

14.

T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1.

Ojwang JO, Buckheit RW, Pommier Y, Mazumder A, De Vreese K, Esté JA, Reymen D, Pallansch LA, Lackman-Smith C, Wallace TL, et al.

Antimicrob Agents Chemother. 1995 Nov;39(11):2426-35.

15.

Construction and characterization of a full-length infectious clone from a fast-replicating, X4-tropic HIV-1 subtype B' isolate.

Wu SL, Yan YS, Yan PP, Huang HL, Wang HR.

Arch Virol. 2010 Dec;155(12):1923-31. doi: 10.1007/s00705-010-0776-z. Epub 2010 Aug 10.

PMID:
20697919
16.

Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.

Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM.

N Engl J Med. 1999 May 27;340(21):1614-22.

17.
19.

The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.

Garvey EP, Johns BA, Gartland MJ, Foster SA, Miller WH, Ferris RG, Hazen RJ, Underwood MR, Boros EE, Thompson JB, Weatherhead JG, Koble CS, Allen SH, Schaller LT, Sherrill RG, Yoshinaga T, Kobayashi M, Wakasa-Morimoto C, Miki S, Nakahara K, Noshi T, Sato A, Fujiwara T.

Antimicrob Agents Chemother. 2008 Mar;52(3):901-8. Epub 2007 Dec 26. Erratum in: Antimicrob Agents Chemother. 2008 May;52(5):1899.

20.

Oligonucleotide-mediated retroviral RNase H activation leads to reduced HIV-1 titer in patient-derived plasma.

Heinrich J, Mathur S, Matskevich AA, Moelling K.

AIDS. 2009 Jan 14;23(2):213-21. doi: 10.1097/QAD.0b013e32831c5480.

PMID:
19098491

Supplemental Content

Support Center